Paper Details

  1. Home
  2. Paper Details

Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.

Author: ChangWen-Hsiung, ChenGuofeng, ChenShijun, ChengJun, DingHuiguo, FanXiaoling, GaoZhiliang, GuanRichard, HouJinlin, HuangWenxiang, LeeTzong-Hsi, LuoDuande, MohamedRosmawati, NingQin, PanChen, RenHong, ShengJifang, TangHong, WanMobin, WangGuiqiang, WangYuming, WeiLai, XieQing, XuDaozhen, YangYuxiu, YeZhang, ZhangJiming, ZhenfeiHuang, ZhouBoping

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Peginterferon alfa-2b 1.5μg/kg/wk for 48 weeks was found to be more efficacious than 1.0 and 1.5μg/kg/wk for 24 weeks in Chinese patients with HBeAg-positive chronic hepatitis B.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In mainland China, peginterferon (PEG-IFN) alfa-2b 1.0μg/kg/wk for 24 weeks is the approved treatment for HBeAg-positive chronic hepatitis B. OBJECTIVE: This multicenter, randomized trial evaluated the safety and efficacy of regimens utilizing increased dose or treatment duration in tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jcv.2014.08.008

データ提供：米国国立医学図書館（NLM）

Peginterferon alfa-2b Treatment for Chronic Hepatitis B: Longer Duration Shows Greater Efficacy

Treating chronic hepatitis B is like navigating a long and winding desert path, full of challenges and uncertainties. This study looked at different dosages and durations of peginterferon alfa-2b treatment for patients with chronic hepatitis B, seeking the most effective approach. The researchers found that a longer treatment duration (48 weeks) with a higher dosage (1.5μg/kg/wk) was more effective in reducing HBeAg levels, a marker of hepatitis B viral activity, compared to shorter treatment durations.

Longer Treatment Duration Leads to Improved Outcomes

The study showed that the longer treatment duration resulted in a significantly higher proportion of patients achieving HBeAg loss, HBe seroconversion (meaning the body developed antibodies to the virus), and HBV DNA levels below 20,000IU/mL, indicating a better response to treatment.

Navigating the Desert of Chronic Hepatitis B

This research offers valuable guidance for treating patients with chronic hepatitis B. While longer treatment durations may seem daunting, they can lead to better outcomes. It's important to consult with a healthcare professional to determine the best course of treatment for your specific situation. Remember, with the right guidance and approach, even the most challenging desert journeys can be conquered.

Dr. Camel's Conclusion

This study provides compelling evidence for the benefits of a longer treatment duration with peginterferon alfa-2b for chronic hepatitis B. Just as a camel can endure long journeys across the desert, patients can also benefit from a longer treatment regimen. This research highlights the importance of tailoring treatment plans to individual needs and working closely with healthcare professionals to navigate the complexities of chronic illness.

Date :
  1. Date Completed 2015-07-14
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25200354

DOI: Digital Object Identifier

10.1016/j.jcv.2014.08.008

Related Literature

Article Analysis
・Effects of peginterferon alfa-2b (peg-intron)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.